A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Bayer
ClinicalTrials.gov Identifier:
NCT01106352
First received: April 16, 2010
Last updated: August 29, 2014
Last verified: August 2014

April 16, 2010
August 29, 2014
July 2010
April 2015   (final data collection date for primary outcome measure)
  • Dose-escalation: Assessment of dose-limiting toxicities [ Time Frame: When 6 weeks post-injection data are available for the first combined injection of Alpharadin/docetaxel ] [ Designated as safety issue: Yes ]
  • Expanded safety cohort: Safety of combining Alpharadin with docetaxel (incidence and severity of adverse events and serious adverse events, changes from baseline in laboratory variables, vital signs and physical examination) [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • Dose-escalation: Assessment of dose-limiting toxicities [ Time Frame: When 6 weeks post-injection data are available for the first combined injection of Alpharadin®/docetaxel ] [ Designated as safety issue: Yes ]
  • Expanded safety cohort: Safety of combining Alpharadin® with docetaxel (incidence and severity of adverse events and serious adverse events, changes from baseline in laboratory variables, vital signs and physical examination) [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT01106352 on ClinicalTrials.gov Archive Site
  • Signs of long-term radiation toxicity: incidence of manifestations of potential late toxicity, such as new primary cancers and bone marrow changes (acute myelogenous leukaemia, myelodysplastic syndrome, and aplastic anaemia) [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • Exploratory efficacy measurements of Alpharadin in combination with docetaxel versus docetaxel alone such as changes in bone markers, PSA and CTC, time to progression and overall survival [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Exploratory patient self-reporting of pain intensity [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • Signs of long-term radiation toxicity: incidence of manifestations of potential late toxicity, such as new primary cancers and bone marrow changes (acute myelogenous leukaemia, myelodysplastic syndrome, and aplastic anaemia) [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • Exploratory efficacy measurements of Alpharadin® in combination with docetaxel versus docetaxel alone such as changes in bone markers, PSA and CTC, time to progression and overall survival [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Exploratory patient self-reporting of pain intensity [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
A Phase I/IIa Study of Safety and Efficacy of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer

The main purpose of this study is to establish a recommended dose of Alpharadin to be used in combination with docetaxel in patients with bone metastases from castration-resistant prostate cancer and to investigate safety and explore efficacy of the recommended dose.

The trial was initially conducted and submitted by Algeta ASA. After acquiring Algeta, Bayer is now the sponsor.

Interventional
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Bone Metastases
  • Castration-Resistant Prostate Cancer
  • Drug: Alpharadin (Radium-223 dichloride) + docetaxel
    Alpharadin (Radium-223 dichloride) is administered intravenously as a bolus injection. In the randomized phase IIa part of the protocol, the dose established in the dose-escalation part of the protocol (Phase I) will be used, i.e. 5 doses of 50 kBq/kg b.w. every 6 weeks in combination with the approved step-down dose of docetaxel (60 mg/m2) administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone.
  • Drug: Docetaxel
    Docetaxel (75 mg/m2) will be administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone. Step-down to 60 mg/m2 is allowed as per the approved docetaxel label.
  • Experimental: Alpharadin + docetaxel
    Intervention: Drug: Alpharadin (Radium-223 dichloride) + docetaxel
  • Active Comparator: Docetaxel alone
    Intervention: Drug: Docetaxel
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
63
April 2015
April 2015   (final data collection date for primary outcome measure)

Main Inclusion Criteria:

  • Histologically or cytologically confirmed adenocarcinoma of the prostate.
  • Two or more bone metastases (hot spots) confirmed by bone scintigraphy within 8 weeks prior to study entry
  • Known castration-resistant disease
  • Karnofsky Performance Status (KPS): ≥70% within 14 days before start of study treatment (ECOG 1)
  • Life expectancy at least 6 months.
  • Acceptable hematology and serum biochemistry screening values
  • Eligible for use of docetaxel according to the product information (package insert or similar).

Main Exclusion Criteria:

  • Has received an investigational therapeutic drug within the last 4 weeks prior to start of study treatment, or is scheduled to receive one during the treatment period.
  • Has received external radiotherapy within the last 4 weeks prior to start of study treatment.
  • Has an immediate need for radiotherapy.
  • Has received prior hemibody external radiotherapy .
  • Has received systemic radiotherapy (e.g. samarium, strontium etc.) for the treatment of bone metastases.
  • Has received cytotoxic chemotherapy within the last 4 weeks prior to start of study treatment, or has not recovered to grade 1 or 0 from adverse events due to cytotoxic chemotherapy administered more than 4 weeks earlier.
  • Has received more than ten previous infusions of docetaxel.
  • Previous known experience of grade ≥ 3 docetaxel related toxicities or docetaxel toxicity related dose interruption or discontinuation.
  • Previous use of G-CSF for persistent neutropenia after docetaxel treatment.
  • Has received blood transfusion or erythropoietin (EPO) within the last 4 weeks prior to start of study treatment.
  • Has received prior treatment with Alpharadin.
  • Malignant lymphadenopathy exceeding 3 cm in short-axis diameter.
  • Symptomatic nodal disease, i.e. scrotal, penile or leg edema.
  • Visceral metastases from CRPC (>2 lung and/or liver metastases [size ≥2cm]), as assessed by CT scan or MRI of the chest/abdomen/pelvis within the last 8 weeks prior to start of study treatment.
  • Uncontrolled loco-regional disease.
  • Other primary tumor (other than CRPC) including haematological malignancy present within the last 5 years (except non-melanoma skin cancer or low-grade superficial bladder cancer).
  • Has imminent or established spinal cord compression based on clinical findings and/or MRI.
  • Unmanageable fecal incontinence.
Male
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   France
 
NCT01106352
15469, BC1-10
No
Bayer
Bayer
Not Provided
Study Director: Bayer Study Director Bayer
Bayer
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP